Q-omics provides the consensus-scored LMO4 profile across patient tissues and cancer cell-line models. LMO4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LMO4 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LMO4 protein abundance shows 19,918 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and KIRC as cancer lineages where LMO4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMO4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMO4 survival associations across molecular data types. LMO4 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMO4 RNA expression–survival associations across cancer types. High LMO4 expression shows unfavorable associations in KIRP, ACC and KICH, but favorable associations in HNSC, OV and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LMO4 RNA expression.
This table summarizes LMO4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LMO4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMO4 shows lower tumor expression in KIRC, BRCA and KICH and higher tumor expression in LIHC, LUSC and CHOL. The KIRC box plot shows higher LMO4 RNA expression in normal versus tumor tissue (log2 FC = −0.601, t-test p < 0.001).
This table shows molecular features associated with LMO4 in patient tissues and cancer cell lines. In patient samples, LMO4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, LMO4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
